Alan Hippe - Roche Holding Chief Financial and IT Officer
| RHHBY Stock | USD 41.06 0.23 0.56% |
Executive
Dr. Alan Hippe was Member of the Corporationrationrate Executive Committee, Chief Financial Officer and Information Technology Officer at Roche Holding Ltd since April 1, 2011. Between 1993 and 1996 Dr. Hippe was Research Assistant and Teaching Assistant at the Universities of Mainz and Mannheim. In 1996 he joined AVECO Holding AG as Head of group controlling and IT systems. He served as Member of the Executive Board of Continental AG from 2002 to 2009. In April 2009 he was appointed Chief Financial Officer and Member of Executive Board of ThyssenKrupp AG. since 2011.
| Age | 56 |
| Tenure | 14 years |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Deborah JD | Gilead Sciences | 60 | |
| Betty Larson | Merck Company | 49 | |
| Linda MD | Novartis AG ADR | 61 | |
| Natalie Bickford | Sanofi ADR | 54 | |
| Giovanni MD | Bristol Myers Squibb | 59 | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Joseph Eiden | Bristol Myers Squibb | 76 | |
| Victoria Whyte | GlaxoSmithKline PLC ADR | N/A | |
| Susan MD | AstraZeneca PLC ADR | 59 | |
| Jackson Egen | Gilead Sciences | N/A | |
| William Winters | Novartis AG ADR | 60 | |
| Pierre Chancel | Sanofi ADR | 68 | |
| Etienne Jousseaume | Novartis AG ADR | N/A | |
| Peter Dannenbaum | Merck Company | N/A | |
| Bertrand Bodson | Novartis AG ADR | 44 | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Jeffrey Pott | AstraZeneca PLC ADR | N/A | |
| Johannes Oosthuizen | Merck Company | 56 | |
| Eric MD | Merck Company | 64 | |
| Samit MD | Bristol Myers Squibb | 56 | |
| Jacquie CFA | Gilead Sciences | N/A | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Claudia Bockstiegel, G Counsel | ||
| Bruno Eschli, Head Relations | ||
| Johannes MD, Head Devel | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Alan Hippe, Chief Financial and IT Officer | ||
| Severin Schwan, CEO and Executive Director | ||
| Pascale Schmidt, Chief Officer |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 293.22 B | |||
| Shares Outstanding | 6.4 B | |||
| Shares Owned By Institutions | 1.27 % | |||
| Price To Earning | 17.56 X | |||
| Price To Book | 9.81 X | |||
| Price To Sales | 3.99 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Roche OTC Stock Analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.